UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | October 6, 2023 |
Accession Number: | 0001013762-23-000161 | ||||||
Submission Type: | POS AM | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | October 6, 2023 |
Accession Number: | 0001013762-23-000161 | ||||||
Submission Type: | POS AM | ||||||
|
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/28/2021 | $1.50 | Buy → Hold | Craig Hallum |
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
DEERFIELD, Ill., June 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on June 22, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under chapter 11 of the U.S. Bankruptcy Code, the Company's securities will be delisted from The Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. As previously announced, Surgalign entered into an asset purchase agreement to
DEERFIELD, Ill., June 20, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) ("Surgalign" or the "Company") a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that the Company has entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors' hardware business outside of the U.S. to Xtant Medical Holdings, Inc. ("Xtant") for $5.0 million. The sale will be effectuated through the chapter 11 proceedings initiated by the Company and certain o
Company to showcase its upgraded HOLO Portal™ Surgical Guidance System and key products in its hardware spine and biologics portfolio DEERFIELD, Ill., May 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced today that it will be exhibiting at ISASS 2023 – the 23rd Annual Conference – sponsored by the International Society for Spine Surgery ("ISASS") and Medical Education Resources. This three-day event will take place June 1-3, 2023 at the Marriott Marquis in San Francisco, CA. The International Society for the Advancement of Spine Surgery i
15-12G - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
Craig Hallum downgraded Surgalign Holdings from Buy to Hold and set a new price target of $1.50
BTIG Research initiated coverage of Surgalign Holdings with a rating of Buy and set a new price target of $4.00
BTIG Research initiated coverage of Surgalign with a rating of Buy